Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.
CRISPR Therapeutics AG (Nasdaq: CRSP) generates frequent news as a gene editing biopharmaceutical company advancing CRISPR/Cas9-based medicines and related platforms. News coverage commonly highlights progress with CASGEVY, described as the world’s first approved CRISPR-based therapy for eligible sickle cell disease and transfusion-dependent beta thalassemia patients, along with updates on the company’s expanding in vivo and cell therapy pipeline.
Investors and observers following CRSP news can expect regular announcements on clinical trial data, such as Phase 1 and Phase 2 results for programs like CTX310 targeting ANGPTL3 for cardiovascular and cardiometabolic disease, and zugo-cel (zugocaptagene geleucel) in autoimmune diseases and B-cell malignancies. Company press releases also report on regulatory milestones and commercialization developments for CASGEVY across multiple regions, including approvals, reimbursement agreements, and pediatric development plans.
CRISPR Therapeutics’ news flow also includes pipeline and platform updates for in vivo liver editing programs (CTX310, CTX320, CTX321, CTX340, CTX450), SyNTase-based CTX460 for alpha-1 antitrypsin deficiency, and regenerative medicine efforts in Type 1 diabetes. Collaboration announcements with partners such as Vertex Pharmaceuticals, Sirius Therapeutics, and Lilly, as well as participation in major scientific and investor conferences, are additional recurring themes.
On Stock Titan’s CRSP news page, readers can review these press releases and third-party articles in one place, track how clinical, regulatory, and partnership developments evolve over time, and use this information as context when assessing CRISPR Therapeutics’ stock and long-term gene editing strategy.
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's senior management team will conduct a fireside chat on Tuesday, April 8, 2025, at 12:45 p.m. ET.
The presentation will be accessible through a live webcast on the company's investor relations website under the 'Events & Presentations' section. Interested parties can access the replay of the webcast, which will remain available for 14 days after the presentation.
CRISPR Therapeutics (Nasdaq: CRSP) announced that Chief Operating Officer Julianne Bruno will step down from her position effective April 11, 2025, to pursue external opportunities. Bruno has served the company for six years, during which her leadership was important in advancing the company's hematology and oncology programs. CEO Samarth Kulkarni acknowledged her contributions in maturing the company's operating model and various cross-functional initiatives.
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's senior management team will deliver a presentation on March 3, 2025, at 10:30 a.m. ET.
Investors and interested parties can access a live webcast of the fireside chat through the company's website under the 'Events & Presentations' section. The presentation recording will remain available for replay on the company's website for 14 days following the event.
CRISPR Therapeutics reports Q4 and full year 2024 results, highlighting significant progress across its portfolio. The company's CASGEVY® treatment continues to gain momentum with more than 50 authorized treatment centers activated globally and over 50 patients having cells collected across all regions by end of 2024.
The company maintains a strong financial position with $1.9 billion in cash and equivalents as of December 31, 2024. Q4 2024 financial results show R&D expenses of $82.2 million (down from $95.1 million in Q4 2023) and G&A expenses of $18.1 million. The company reported a net loss of $37.3 million for Q4 2024, compared to net income of $89.3 million in Q4 2023.
Key developments include ongoing clinical trials for next-generation CAR T products CTX112™ and CTX131™, and in vivo gene editing candidates CTX310™ and CTX320™. The company also established a strategic partnership with Nkure Therapeutics for CTX112 development in India.
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company specializing in gene-based medicines for serious diseases, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The company's senior management team will deliver a presentation on Wednesday, February 5, 2025, at 2:00 p.m. ET.
The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section. Interested parties can view the fireside chat through the investor relations portal at https://crisprtx.gcs-web.com/events. The recording will remain available for replay on the company's website for 14 days after the presentation.
CRISPR Therapeutics (Nasdaq: CRSP) has outlined its strategic priorities and anticipated milestones for 2025. The company is starting the year with approximately $1.9 billion in cash and marketable securities, driven by the successful launch of CASGEVY®. CASGEVY has seen strong global demand, with over 50 patients initiating cell collection and more than 50 Authorized Treatment Centers (ATCs) established globally.
Key priorities for 2025 include advancing pipeline candidates such as CTX112™ in oncology and autoimmune diseases, and CTX310™ and CTX320™ in cardiovascular indications. The company also focuses on next-generation gene editing and lipid nanoparticle (LNP) delivery platforms.
Significant updates are expected in 2025, including quarterly updates on CASGEVY, clinical data updates for CTX310 and CTX320 in the first half of the year, and a broad update on CTX112 in mid-2025. Additional updates are anticipated for CTX131 and regenerative medicine programs.
CRISPR Therapeutics has made progress in its immuno-oncology and autoimmune disease programs, with CTX112 showing strong efficacy in Phase 1/2 trials. The company also plans to expand trials for CTX112 in systemic lupus erythematosus, systemic sclerosis, and inflammatory myositis. Furthermore, advancements are being made in in vivo cardiovascular programs and regenerative medicine, including trials for Type 1 diabetes treatments.
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company dedicated to developing transformative gene-based medicines for serious diseases, announced that its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference.
The presentation is scheduled for Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the 'Events & Presentations' page in the Investors section of the company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the company's website for 14 days following the presentation.
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on gene-based medicines for serious diseases, announced the proposed election of Briggs Morrison, M.D. to its Board of Directors at the upcoming annual general meeting. CEO Samarth Kulkarni emphasized Dr. Morrison's extensive pharmaceutical industry experience and clinical development expertise as valuable assets for advancing the company's innovative platform and pipeline.
Dr. Morrison, currently the CEO and Board member of Crossbow Therapeutics, Inc., expressed enthusiasm about joining CRISPR Therapeutics. With over 30 years in the pharmaceutical and biotechnology sectors, he has held executive roles at Syndax Pharmaceuticals, AstraZeneca, Pfizer, and Merck. He has overseen clinical development from Phase 1 to approval for several drugs, including Tagrisso®, Imfinzi®, and Lynparza®.
Dr. Morrison also serves on the boards of various biotechnology companies and is an Entrepreneur Partner at MPM BioImpact. He holds a B.S. in Biology from Georgetown University and an M.D. from the University of Connecticut.
CRISPR Therapeutics presented data from their Phase 1/2 clinical trial of CTX112™, a next-generation CD19 allogeneic CAR T cell therapy, showing promising results in treating relapsed or refractory B-cell malignancies. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for treating R/R follicular lymphoma and marginal zone lymphoma.
Key findings include:
- 67% objective response rate across all dose levels
- 50% complete response rate
- Well-tolerated safety profile with no Grade ≥3 infections
- Five patients achieved responses lasting over 6 months
The trial involved 12 subjects treated with varying doses, demonstrating dose-dependent efficacy. CTX112 is also being tested in a Phase 1 trial for systemic lupus erythematosus, with potential expansion into other autoimmune indications. A broader update across indications is expected in mid-2025.
CRISPR Therapeutics (Nasdaq: CRSP) has announced its participation in the upcoming Jefferies London Healthcare Conference. CEO and Chairman Samarth Kulkarni, Ph.D., will deliver a presentation on Wednesday, November 20, 2024, at 4:00 p.m. GMT. The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section, with a replay available for 14 days afterward. CRISPR Therapeutics specializes in developing transformative gene-based medicines for serious diseases.